Novartis announced the U.S. FDA has approved Cosentyx (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in four years and older, and active juvenile psoriatic…
argenx announced the U.S. FDA has approved Vyvgart (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor…
Calliditas Therapeutics announced the U.S FDA has granted accelerated approval for Tarpeyo (budesonide) delayed release capsules to reduce proteinuria in adults with primary IgA nephropathy…
UCB Pharma announced positive topline results from the Phase 3 MycarinG study evaluating rozanolixizumab, a subcutaneously (SC) infused monoclonal antibody), versus placebo in adults with generalized…
AbbVie announced positive top-line results from U-EXCEED, a Phase 3 induction study, in patients with moderate to severe Crohn’s disease who had an inadequate response…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
